Sylva L. U. Schwager

2.8k citations

45 papers · 2.3k indexed · 1 hit paper · h-index 24

Molecular Biology top 5%
Cardiology and Cardiovascular Medicine top 5%
Computational Theory and Mathematics top 1%
Oncology top 10%
Insect Science top 2%

Co-authors: Edward D. Sturrock K. Ravi Acharya R. Natesh Mario R. Ehlers Hazel R. Evans Geoffrey Masuyer Hazel Corradi Adriana K. Carmona
Topics: Peptidase Inhibition and Analysis (17 papers)Renin-Angiotensin System Studies (15 papers)Chemical Synthesis and Analysis (12 papers)
Cited by: Computational Theory and Mathematics Insect Science Cardiology and Cardiovascular Medicine
Journals: Nature Journal of Biological Chemistry PLoS ONE
Partner nations: South Africa United Kingdom United States

In The Last Decade

Sylva L. U. Schwager

44 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Crystal structure of the human angiotensin-converting enzyme–lisinopril complex

2003 712 citations R. Natesh, Sylva L. U. Schwager et al. Nature profile →

Peers

Countries citing papers authored by Sylva L. U. Schwager

Since Specialization

Citations

This map shows the geographic impact of Sylva L. U. Schwager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylva L. U. Schwager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylva L. U. Schwager more than expected).

Fields of papers citing papers by Sylva L. U. Schwager

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylva L. U. Schwager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylva L. U. Schwager. The network helps show where Sylva L. U. Schwager may publish in the future.

Co-authorship network of co-authors of Sylva L. U. Schwager

This figure shows the co-authorship network connecting the top 25 collaborators of Sylva L. U. Schwager. A scholar is included among the top collaborators of Sylva L. U. Schwager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylva L. U. Schwager. Sylva L. U. Schwager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Design of Novel Mercapto-3-phenylpropanoyl Dipeptides as Dual Angiotensin-Converting Enzyme C–Domain-Selective/Neprilysin Inhibitors 2025 ·Journal of Medicinal Chemistry ·Gyles E. Cozier,(unknown),Charles J. Eyermann,Gregory S. Basarab,Sylva L. U. Schwager,Kelly Chibale,Edward D. Sturrock,K. Ravi Acharya	0
2	Structural basis for the inhibition of human angiotensin‐1 converting enzyme by fosinoprilat 2022 ·FEBS Journal ·Gyles E. Cozier,(unknown),Sylva L. U. Schwager,R. Elwyn Isaac,Edward D. Sturrock,K. Ravi Acharya	3
3	Investigation into the Mechanism of Homo- and Heterodimerization of Angiotensin-Converting Enzyme 2018 ·Molecular Pharmacology ·(unknown),(unknown),Gyles E. Cozier,Sylva L. U. Schwager,K. Ravi Acharya,Edward D. Sturrock	5
4	Therapeutic drug monitoring of amlodipine and the Z-FHL/HHL ratio: Adherence tools in patients referred for apparent treatment-resistant hypertension 2017 ·South African Medical Journal ·Erika Jones,Maia Lesosky,(unknown),Sandra Castel,Eric Decloedt,Sylva L. U. Schwager,Edward D. Sturrock,Lubbe Wiesner,Brian Rayner	7
5	Kinetic and structural characterization of amyloid‐β peptide hydrolysis by human angiotensin‐1‐converting enzyme 2016 ·FEBS Journal ·(unknown),Geoffrey Masuyer,Ross G. Douglas,Sylva L. U. Schwager,K. Ravi Acharya,Edward D. Sturrock	18
6	A Novel Angiotensin I-Converting Enzyme Mutation (S333W) Impairs N-Domain Enzymatic Cleavage of the Anti-Fibrotic Peptide, AcSDKP 2014 ·PLoS ONE ·Sergei M. Danilov,Michael S. Wade,Sylva L. U. Schwager,Ross G. Douglas,Andrew B. Nesterovitch,(unknown),Kyle Hogarth,(unknown),David E. Schwartz,Edward D. Sturrock,Joe G. N. Garcia	21
7	Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor 2014 ·European Journal of Pharmaceutical Sciences ·Paolo Denti,(unknown),(unknown),Sylva L. U. Schwager,Aman Mahajan,Mathew Njoroge,Liezl Gibhard,(unknown),Kelly Chibale,Lubbe Wiesner,Edward D. Sturrock,Neil H. Davies	15
8	Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides 2012 ·Scientific Reports ·Geoffrey Masuyer,Sylva L. U. Schwager,Edward D. Sturrock,R. Elwyn Isaac,K. Ravi Acharya	131
9	Shedding the load of hypertension: The proteolytic processing of angiotensin-converting enzyme 2012 ·South African Medical Journal ·Mario R. Ehlers,(unknown),Sylva L. U. Schwager,Edward D. Sturrock	13
10	Structural characterization of angiotensin I‐converting enzyme in complex with a selenium analogue of captopril 2011 ·FEBS Journal ·Mohd Akif,Geoffrey Masuyer,Sylva L. U. Schwager,(unknown),Govindasamy Mugesh,R. Elwyn Isaac,Edward D. Sturrock,K. Ravi Acharya	26
11	The N Domain of Human Angiotensin-I-converting Enzyme 2010 ·Journal of Biological Chemistry ·Colin Anthony,Hazel Corradi,Sylva L. U. Schwager,Pierre Redelinghuys,Dimitris Georgiadis,Vincent Dive,K. Ravi Acharya,Edward D. Sturrock	76
12	A continuous fluorescence resonance energy transfer angiotensin I-converting enzyme assay 2006 ·Nature Protocols ·Adriana K. Carmona,Sylva L. U. Schwager,María A. Juliano,Luiz Juliano,Edward D. Sturrock	86
13	A high-throughput fluorimetric assay for angiotensin I-converting enzyme 2006 ·Nature Protocols ·Sylva L. U. Schwager,Adriana K. Carmona,Edward D. Sturrock	45
14	Crystal Structure of the N Domain of Human Somatic Angiotensin I-converting Enzyme Provides a Structural Basis for Domain-specific Inhibitor Design 2006 ·Journal of Molecular Biology ·Hazel Corradi,Sylva L. U. Schwager,Aloysius T. Nchinda,Edward D. Sturrock,K. Ravi Acharya	133
15	Structural Details on the Binding of Antihypertensive Drugs Captopril and Enalaprilat to Human Testicular Angiotensin I-Converting Enzyme ^, 2004 ·Biochemistry ·R. Natesh,Sylva L. U. Schwager,Hazel R. Evans,Edward D. Sturrock,K. Ravi Acharya	234
16	Deletion of the cytoplasmic domain increases basal shedding of angiotensin-converting enzyme 2004 ·Biochemical and Biophysical Research Communications ·Anthony J. Chubb,Sylva L. U. Schwager,Elizabeth van der Merwe,Mario R. Ehlers,Edward D. Sturrock	4
17	The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein 2004 ·European Journal of Biochemistry ·(unknown),Edward T. Parkin,Thomas P. Condon,Sylva L. U. Schwager,Edward D. Sturrock,Anthony J. Turner,Nigel M. Hooper	72
18	Crystal structure of the human angiotensin-converting enzyme–lisinopril complexbreakdown → 2003 ·Nature ·R. Natesh,Sylva L. U. Schwager,Edward D. Sturrock,K. Ravi Acharya	712
19	Roles of the juxtamembrane and extracellular domains of angiotensin-converting enzyme in ectodomain shedding 2001 ·Biochemical Journal ·(unknown),Anthony J. Chubb,Sylva L. U. Schwager,Mario R. Ehlers,Edward D. Sturrock,Nigel M. Hooper	33
20	Proteolytic release of membrane proteins: studies on a membrane-protein-solubilizing activity in CHO cells 1997 ·Immunopharmacology ·Mario R. Ehlers,Sylva L. U. Schwager,Anthony J. Chubb,Renate R. Scholle,Wolf F. Brandt,James Riordan	7

About Sylva L. U. Schwager

Sylva L. U. Schwager is a scholar working on Genetics, Cardiology and Cardiovascular Medicine and Oncology, having authored 45 papers that have together received 2.3k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (17 papers), Renin-Angiotensin System Studies (15 papers) and Chemical Synthesis and Analysis (12 papers). The work is most often cited by research in Computational Theory and Mathematics (465 citations), Insect Science (337 citations) and Cardiology and Cardiovascular Medicine (572 citations). Sylva L. U. Schwager has collaborated with scholars based in South Africa, United Kingdom and United States. Frequent co-authors include Edward D. Sturrock, K. Ravi Acharya, R. Natesh, Mario R. Ehlers, Hazel R. Evans, Geoffrey Masuyer, Hazel Corradi, Adriana K. Carmona, R. Elwyn Isaac and Wolf F. Brandt. Their work appears in journals such as Nature, Journal of Biological Chemistry and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact